Dataset Information

Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic antigenic peptides

ABSTRACT: Mass spectrometry for HLA class I (HLA-I) peptidome of human breast cancer samples identified an HLA-I binding peptide encoded by circRNA.

ORGANISM(S): Homo Sapiens Mus Musculus

SUBMITTER: Shicheng Su

PROVIDER: PXD041427 | iProX | Thu Dec 21 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Publications

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides.

Huang Di D Zhu Xiaofeng X Ye Shuying S Zhang Jiahui J Liao Jianyou J Zhang Ning N Zeng Xin X Wang Jiawen J Yang Bing B Zhang Yin Y Lao Liyan L Chen Jianing J Xin Min M Nie Yan Y Saw Phei Er PE Su Shicheng S Song Erwei E

Nature 20231213 7995

Emerging data have shown that previously defined noncoding genomes might encode peptides that bind human leukocyte antigen (HLA) as cryptic antigens to stimulate adaptive immunity<sup>1,2</sup>. However, the significance and mechanisms of action of cryptic antigens in anti-tumour immunity remain unclear. Here mass spectrometry of the HLA class I (HLA-I) peptidome coupled with ribosome sequencing of human breast cancer samples identified HLA-I-binding cryptic antigenic peptides that were noncanon ...[more]

PMID: 38093017

Similar Datasets

Project description:Treatment of cancer cells with anti-cancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumorâs gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA peptides on the surface of the tumor cells and be developed into anti-cancer immunotherapeutics. For example, the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine (Decitabine) has limited anti-tumor efficacy, yet it induces the expression of many genes, including CTAs that are normally silenced in the healthy adult tissues. In this study, the presentation of many new HLA peptides derived from CTAs and induced by Decitabine was demonstrated in three human Glioblastoma cell lines. Such presentation of CTA-derived HLA peptides can be exploited for development of new treatment modalities, combining drug treatment with anti-CTA targeted immunotherapy. The Decitabine-induced HLA peptidomes include many CTAs that are not normally detected in healthy tissues or in cancer cells, unless treated with the drug. In addition, the study included large-scale analyses of the simultaneous effects of Decitabine on the transcriptomes, proteomes and HLA peptidomes of the human Glioblastoma cells. It demonstrates the poor correlations between these three levels of gene expression, both in their total levels and in their response to the drug. The transcriptomes, proteomes and HLA peptidomes of the U-87, T98G and LNT-229 GBM human cell lines were analyzed before and after treatment with Decitabine. Overall, the RNA-Seq transcriptome analyses resulted in the identification of above 26000 transcripts, the proteome analyses identified about 7500 proteins and the HLA class I peptidome analyses resulted in above 25000 identified HLA peptides. Two biological repetitions of the transcriptome, three of the proteome and three of the HLA peptidome were performed with each of the cell lines and treatment, resulting in highly reproducible datasets.

Dataset Information

Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic antigenic peptides

Publications

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets